Irlon Ferreira

Dr. Irlon Ferreira

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
RBRaphaelle Sousa Borges
Raphaelle Sousa Borges
HKHady Keita
Hady Keita
BOBrenda Lorena Sánchez Ortiz
Brenda Lorena Sánchez Ortiz
TSTafnis Ingret dos Santos Sampaio
Tafnis Ingret dos Santos Sampaio
Irlon FerreiraIrlon Ferreira
Irlon Ferreira
José Carlos Tavares CarvalhoJosé Carlos Tavares Carvalho
José Carlos Tavares Carvalho

1 April 2015 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
BVBruna Vacondio
Bruna Vacondio
Willian Garcia BirolliWillian Garcia Birolli
Willian Garcia Birolli
Irlon FerreiraIrlon Ferreira
Irlon Ferreira
MSMirna H.R. Seleghim
Mirna H.R. Seleghim
SGSarah Gonçalves
Sarah Gonçalves
André Luiz Meleiro PortoAndré Luiz Meleiro Porto
André Luiz Meleiro Porto

5 February 2020 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
MRMatheus M. Ramos
Matheus M. Ramos
EMEdmilson dos S. Morais
Edmilson dos S. Morais
ISIracirema da S. Sena
Iracirema da S. Sena
ALAdilson L. Lima
Adilson L. Lima
FOFábio Rodrigues Oliveira
Fábio Rodrigues Oliveira
Irlon FerreiraIrlon Ferreira
Irlon Ferreira

13 July 2017 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
RBRaphaelle Sousa Borges
Raphaelle Sousa Borges
ELEmerson Lima
Emerson Lima
HKHady Keita
Hady Keita
Irlon FerreiraIrlon Ferreira
Irlon Ferreira
Caio FernandesCaio Fernandes
Caio Fernandes
JCJosé Carlos Tavares Carvalho
José Carlos Tavares Carvalho

4 November 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
RNRaimundo de A. M. Neto
Raimundo de A. M. Neto
Cleydson Breno Rodrigues dos SantosCleydson Breno Rodrigues dos Santos
Cleydson Breno Rodrigues dos Santos
SHShayanne V. C. Henriques
Shayanne V. C. Henriques
LMLetícia de O. Machado
Letícia de O. Machado
Jorddy N. CruzJorddy N. Cruz
Jorddy N. Cruz
MGMadson R. F. Gomes
Madson R. F. Gomes
Glioblastoma is an aggressive primary tumor of the central nervous system (CNS). Is the most aggressive among infiltrative gliomas arising from the CNS. This tumor has low patient survival rate and several studies aiming at developing new drugs have increased. Patients with this cancer type face significant morbidity and mortality. This study evaluated the antineoplastic activity of synthetic chalcones (3a-3f) using in vitro glioblastoma models and molecular modeling. Cytotoxicity assay showed that Astrocitoma Hospital Ofir Loyola No 1 (AHOL1) and Uppsala 87 neoplastic glioblastoma lines (U87) cellular viability were significantly reduced compared to Healthy human fibroblasts cell lines (AN27) when exposed to chalcones. Interaction with the serine amino acid was present in the most promising and the reference binder docking, suggesting its importance inhibiting cell growth. Comparative analysis between the reference ligands and the molecules showed that the amino acid LYS352 present in all fittings, suggesting that this is the main amino acid for interaction with tubulin and are consistent with those in cytotoxicity assay, suggesting antineoplastic potential in glioblastoma. Long trajectory molecular dynamics studies were also carried out in order to investigate stability and conformations amongst the chalcones bound tubulin as well, in comparison to doxorubicin (here used as control), however future studies are needed to further assess the mechanism of inhibition of chalcones used in this investigation. Communicated by Ramaswamy H. Sarma

20 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AFAdriana Maciel Ferreira
Adriana Maciel Ferreira
ASAgerdânio Andrade de Souza
Agerdânio Andrade de Souza
RKRosemary de Carvalho Rocha Koga
Rosemary de Carvalho Rocha Koga
ISIracirema S. Sena
Iracirema S. Sena
MMMateus de Jesus S. Matos
Mateus de Jesus S. Matos
José Carlos Tavares CarvalhoJosé Carlos Tavares Carvalho
José Carlos Tavares Carvalho
Melanogenesis is a biosynthetic pathway for the formation of the pigment melanin in human skin. A key enzyme in the process of pigmentation through melanin is tyrosinase, which catalyzes the first and only limiting step in melanogenesis. Since the discovery of its methanogenic properties, tyrosinase has been the focus of research related to the anti-melanogenesis. In addition to developing more effective and commercially safe inhibitors, more studies are required to better understand the mechanisms involved in the skin depigmentation process. However, in vivo assays are necessary to develop and validate new drugs or molecules for this purpose, and to accomplish this, zebrafish has been identified as a model organism for in vivo application. In addition, such model would allow tracking and studying the depigmenting activity of many bioactive compounds, important to genetics, medicinal chemistry and even the cosmetic industry. Studies have shown the similarity between human and zebrafish genomes, encouraging their use as a model to understand the mechanism of action of a tested compound. Interestingly, zebrafish skin shares many similarities with human skin, suggesting that this model organism is suitable for studying melanogenesis inhibitors. Accordingly, several bioactive compounds reported herein for this model are compared in terms of their molecular structure and possible mode of action in zebrafish embryos. In particular, this article described the main metabolites of Trichoderma fungi, in addition to substances from natural and synthetic sources.